Ovid Therapeutics
Ovid Therapeutics
OVID
NASDAQ
0.44
USD
0.00%
About
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms.
It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions.
It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 245.6K |
| Three Month Average Volume | 19.9M |
| High Low | |
| Fifty-Two Week High | 4.1 USD |
| Fifty-Two Week Low | 0.68 USD |
| Fifty-Two Week High Date | 12 Feb 2024 |
| Fifty-Two Week Low Date | 26 Jun 2024 |
| Price and Volume | |
| Current Price | 1.13 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 11.41% |
| Thirteen Week Relative Price Change | -65.50% |
| Twenty-Six Week Relative Price Change | -69.77% |
| Fifty-Two Week Relative Price Change | -73.20% |
| Year-to-Date Relative Price Change | -70.37% |
| Price Change | |
| One Day Price Change | -5.83% |
| Thirteen Week Price Change | -63.07% |
| Twenty-Six Week Price Change | -66.76% |
| Five Day Price Change | -6.61% |
| Fifty-Two Week Price Change | -66.42% |
| Year-to-Date Price Change | -64.91% |
| Month-to-Date Price Change | 8.65% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.24196 USD |
| Book Value Per Share (Most Recent Quarter) | 1.25266 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.23938 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.24957 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.95445 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00555 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00802 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.74155 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.42177 USD |
| Normalized (Last Fiscal Year) | -0.74155 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.74155 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.42129 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.74155 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.42177 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.49711 USD |
| Cash Per Share (Most Recent Quarter) | 1.08457 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.7335 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.41207 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.74965 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -39 |
| Cash Flow Revenue (Trailing Twelve Months) | -9,353 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -5,241.56% |
| Pretax Margin (Last Fiscal Year) | -13,362.00% |
| Pretax Margin (5 Year) | -55.56% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -15,134.40% |
| Operating Margin (Trailing Twelve Months) | -12,008.38% |
| Operating Margin (5 Year) | -59.88% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -13,362.00% |
| Net Profit Margin (Trailing Twelve Months) | -5,241.56% |
| Net Profit Margin (5 Year) | -56.16% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -4.63% |
| Tangible Book Value (5 Year) | 17.69% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 125.33% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 185.85% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -68.57% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -17.14% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 168.03% |
| EPS Change (Trailing Twelve Months) | 39.62% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -76,974,000 |
| Net Debt (Last Fiscal Year) | -105,833,400 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 205 |
| Price to Sales (Trailing Twelve Months) | 141 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 3 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 2 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 10 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -45,918,390 |
| Free Cash Flow (Trailing Twelve Months) | -53,079,790 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -34.98% |
| Return on Assets (Trailing Twelve Months) | -23.39% |
| Return on Assets (5 Year) | -20.78% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -47.57% |
| Return on Equity (Trailing Twelve Months) | -29.81% |
| Return on Equity (5 Year) | -26.21% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -37.27% |
| Return on Investment (Trailing Twelve Months) | -25.86% |
| Return on Investment (5 Year) | -23.27% |